Oncoinvent plans private placement raising up to NOK 140 million at NOK 90 a share

By Public Technologies
  • Oncoinvent retained ABG Sundal Collier, DNB Carnegie for a private placement of new shares raising up to NOK 140 million.
  • Offer price fixed at NOK 90 per share; bookbuilding opens today 16:30 CEST, closes Sept. 23 at 08:00 CEST.
  • Minimum application set at the NOK equivalent of EUR 100,000; allocation set by the board with full allocation to pre-committed investors.
  • Two largest shareholders pre-committed NOK 17.4 million and NOK 17.3 million; CEO, CFO, chair, COO, board member also subscribe.
  • Proceeds target phase 2 readout in March/April 2027, full recruitment in H1 2027, regulatory alignment, phase 3 readiness; runway into H2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncoinvent ASA published the original content used to generate this news brief via Cision (Ref. ID: 20260922:BIT:3886:0) on September 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.